| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Chief Business Officer
2 companies
Scott Jordan last filed a Form 4 in March 2025, as Chief Financial Officer at ZOMDF. The filings on record cover 2 companies. Scott Jordan's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 31,609 shares of DCOY. Net of sales, the DCOY filings show accumulation of 11,300 shares.
Scott Jordan has 4 Form 4 filings on record from September 2019 to March 2025, across 2 companies: Chief Financial Officer at Zomedica (ZOMDF), 2025; Chief Business Officer at Salarius Pharmaceuticals (DCOY), 2019–2020.
The 4 reported transactions were 2 open-market purchases and 2 option or other derivative awards.
Counted by filing, the open-market trades come to 2 purchases worth about $29K and no sales.
The largest open-market purchase was 300,000 shares of ZOMDF at an average $0.06 on March 17, 2025, about $19K.
Shares as reported in the last Form 4 for each company; the most recent is from March 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.